166 related articles for article (PubMed ID: 27629142)
21. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.
Li YP; Chen JJ; Shen JJ; Cui J; Wu LZ; Wang Z; Li ZR
Cancer Chemother Pharmacol; 2015 Apr; 75(4):773-82. PubMed ID: 25681003
[TBL] [Abstract][Full Text] [Related]
22. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
23. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
24. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
[TBL] [Abstract][Full Text] [Related]
25. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo.
Lesko E; Gozdzik J; Kijowski J; Jenner B; Wiecha O; Majka M
Anticancer Drugs; 2007 Nov; 18(10):1173-81. PubMed ID: 17893518
[TBL] [Abstract][Full Text] [Related]
26. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
[TBL] [Abstract][Full Text] [Related]
27. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
Schumacher JA; Crockett DK; Elenitoba-Johnson KS; Lim MS
Proteomics; 2007 Aug; 7(15):2603-16. PubMed ID: 17610208
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological inhibition of HSP90 activity negatively modulates myogenic differentiation and cell survival in C2C12 cells.
Wagatsuma A; Shiozuka M; Kotake N; Takayuki K; Yusuke H; Mabuchi K; Matsuda R; Yamada S
Mol Cell Biochem; 2011 Dec; 358(1-2):265-80. PubMed ID: 21739150
[TBL] [Abstract][Full Text] [Related]
30. Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells.
Mori M; Hitora T; Nakamura O; Yamagami Y; Horie R; Nishimura H; Yamamoto T
Int J Oncol; 2015 Jan; 46(1):47-54. PubMed ID: 25351442
[TBL] [Abstract][Full Text] [Related]
31. Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: involvement of p38 MAPK activation.
Zhang B; Wang X; Cai F; Chen W; Loesch U; Zhong XY
Oncol Rep; 2013 Apr; 29(4):1371-8. PubMed ID: 23338561
[TBL] [Abstract][Full Text] [Related]
32. Geldanamycin interferes with the 90-kDa heat shock protein, affecting lipopolysaccharide-mediated interleukin-1 expression and apoptosis within macrophages.
Hsu HY; Wu HL; Tan SK; Li VP; Wang WT; Hsu J; Cheng CH
Mol Pharmacol; 2007 Jan; 71(1):344-56. PubMed ID: 16868182
[TBL] [Abstract][Full Text] [Related]
33. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
[TBL] [Abstract][Full Text] [Related]
34. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
Hu Y; Bobb D; He J; Hill DA; Dome JS
Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection.
Demidenko ZN; Vivo C; Halicka HD; Li CJ; Bhalla K; Broude EV; Blagosklonny MV
Cell Death Differ; 2006 Sep; 13(9):1434-41. PubMed ID: 16311509
[TBL] [Abstract][Full Text] [Related]
36. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Lombardi R; Sonego M; Pucci B; Addi L; Iannelli F; Capone F; Alfano L; Roca MS; Milone MR; Moccia T; Costa A; Di Gennaro E; Bruzzese F; Baldassarre G; Budillon A
Mol Oncol; 2021 Apr; 15(4):1005-1023. PubMed ID: 33331136
[TBL] [Abstract][Full Text] [Related]
37. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
[TBL] [Abstract][Full Text] [Related]
38. The relationship between p38MAPK and apoptosis during paclitaxel resistance of ovarian cancer cells.
Lu M; Xiao L; Li Z
J Huazhong Univ Sci Technolog Med Sci; 2007 Dec; 27(6):725-8. PubMed ID: 18231754
[TBL] [Abstract][Full Text] [Related]
39. [Effect of HSP90 function inhibited on the telomerase and P53 mutant in breast cancer cells].
Li X; Deng HY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 39(2):181-3. PubMed ID: 18630678
[TBL] [Abstract][Full Text] [Related]
40. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
Blagosklonny MV; Fojo T; Bhalla KN; Kim JS; Trepel JB; Figg WD; Rivera Y; Neckers LM
Leukemia; 2001 Oct; 15(10):1537-43. PubMed ID: 11587211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
